|
[1] GAO B,BATALLER R. Alcoholic liver disease:Pathogenesis and new therapeutic targets[J]. Gastroenterology,2011,141(5):1572-1585.
|
|
[2] WHO. Global Health Estimates 2015:Deaths by cause,age,sex,by country and by region,2000-2015[EB/OL].(2016)https://www. who. int/healthinfo/global_burden_disease/estimates_regional_2000_2015/en/．
|
|
[3] STICKEL F,BUCH S,LAU K,et al. Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians[J]. Hepatology,2011,53(1):86-95.
|
|
[4] TIAN C,STOKOWSKI RP,KERSHENOBICH D,et al. Variant in PNPLA3 is associated with alcoholic liver disease[J]. Nat Genet,2010,42(1):21-23.
|
|
[5] TRPO E,GUSTOT T,DEGRD,et al. Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease[J]. J Hepatol,2011,55(4):906-912.
|
|
[6] BURZA MA,MOLINARO A,ATTILIA ML,et al. PNPLA3 I148M(rs738409)genetic variant and age at onset of at-risk alcohol consumption are independent risk factors for alcoholic cirrhosis[J]. Liver Int,2014,34(4):514-520.
|
|
[7] BUCH S,STICKEL F,TRPO E,et al. A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis[J]. Nat Genet,2015,47(12):1443-1448.
|
|
[8] ZHANG Y,GUO T,YANG F,et al. Single-nucleotide rs738409polymorphisms in the PNPLA3 gene are strongly associated with alcoholic liver disease in Han Chinese males[J]. Hepatol Int,2018,12(5):429-437.
|
|
[9] STICKEL F,BUCH S,NISCHALKE HD,et al. Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis[J]. Am J Gastroenterol,2018,113(10):1475-1483.
|
|
[10] ABUL-HUSN NS,CHENG X,LI AH,et al. A protein-truncating HSD17B13 variant and protection from chronic liver disease[J]. N Engl J Med,2018,378(12):1096-1106.
|
|
[11] SU W,MAO Z,LIU Y,et al. Role of HSD17B13 in the liver physiology and pathophysiology[J]. Mol Cell Endocrinol,2019,489:119-125.
|
|
[12] LIU S,HUANG C,LI D,et al. Molecular cloning and expression analysis of a new gene for short-chain dehydrogenase/reductase 9[J]. Acta Biochim Pol,2007,54(1):213-218.
|
|
[13] ZHANG X,WANG Y,LIU P. Omic studies reveal the pathogenic lipid droplet proteins in non-alcoholic fatty liver disease[J]. Protein Cell,2017,8(1):4-13.
|
|
[14] SU W,WANG Y,JIA X,et al. Comparative proteomic study reveals 17β-HSD13 as a pathogenic protein in nonalcoholic fatty liver disease[J]. Proc Natl Acad Sci U S A,2014,111(31):11437-11442.
|
|
[15] ADAM M,HEIKELH,SOBOLEWSKI C,et al. Hydroxysteroid(17β)dehydrogenase 13 deficiency triggers hepatic steatosis and inflammation in mice[J]. FASEB J,2018,32(6):3434-3447.
|
|
[16] MA Y,BELYAEVA OV,BROWN PM,et al. 17-beta hydroxysteroid dehydrogenase 13 is a hepatic retinol dehydrogenase associated with histological features of nonalcoholic fatty liver disease[J]. Hepatology,2019,69(4):1504-1519.
|
|
[17] SEITZ HK,BATALLER R,CORTEZ-PINTO H,et al. Alcoholic liver disease[J]. Nat Rev Dis Primers,2018,4(1):16.
|
|
[18] BARAONA E,LIEBER CS. Effects of ethanol on lipid metabolism[J]. J Lipid Res,1979,20(3):289-315.
|
|
[19] JEON S,CARR R. Alcohol effects on hepatic lipid metabolism[J]. J Lipid Res,2020,61(4):470-479.
|
|
[20] SU W,PENG J,LI S,et al. Liver X receptorαinduces 17β-hydroxysteroid dehydrogenase-13 expression through SREBP-1c[J]. Am J Physiol Endocrinol Metab,2017,312(4):e357-e367.
|
|
[21] ANSARI RA,HUSAIN K,RIZVI SA. Role of transcription factors in steatohepatitis and hypertension after ethanol:The epicenter of metabolism[J]. Biomolecules,2016,6(3):29.
|
|
[22] de AZEVEDO LA,MATTE U,da SILVEIRA TR,et al. Genetic variants underlying vitamin D metabolism and VDR-TGFβ-1-SMAD3 interaction may impact on HCV progression:A study based on dbGaP data from the HALT-C study[J]. J Hum Genet,2017,62(11):969-977.
|
|
[23] STICKEL F,LUTZ P,BUCH S,et al. Genetic variation in HSD17B13 reduces the risk of developing cirrhosis and hepatocellular carcinoma in alcohol misusers[J]. Hepatology,2020,72(1):88-102.
|
|
[24] GELLERT-KRISTENSEN H,NORDESTGAARD BG,TYBJAERGHANSEN A,et al. High risk of fatty liver disease amplifies the alanine transaminase-lowering effect of a HSD17B13 variant[J].Hepatology,2020,71(1):56-66.
|
|
[25] YANG J,TRPO E,NAHON P,et al. A 17-beta-hydroxysteroid dehydrogenase 13 variant protects from hepatocellular carcinoma development in alcoholic liver disease[J]. Hepatology,2019,70(1):231-240.
|
|
[26] XU G,YANG F,DING CL,et al. Small nucleolar RNA 113-1suppresses tumorigenesis in hepatocellular carcinoma[J].Mol Cancer,2014,13:216.
|
|
[27] CHEN J,ZHUO JY,YANG F,et al. 17-beta-hydroxysteroid dehydrogenase 13 inhibits the progression and recurrence of hepatocellular carcinoma[J]. Hepatobiliary Pancreat Dis Int,2018,17(3):220-226.
|
|
[28] ZENG CM,YAN ML,SHI YH,et al. Changes in the expression of 17-β-hydroxysteroid dehydrogenase 13 and mitofusin 2 in liver cancer tissue and a bioinformatics analysis[J].J Clin Hepatol,2019,35(12):2736-2740.(in Chinese)曾钗明，严茂林，石益海，等．17β羟基类固醇脱氢酶13和线粒体融合蛋白2在肝细胞癌组织中的表达变化及生物信息学分析[J]．临床肝胆病杂志，2019,35(12):2736-2740.
|
|
[29] WANG X,LIAO X,YANG C,et al. Identification of prognostic biomarkers for patients with hepatocellular carcinoma after hepatectomy[J]. Oncol Rep,2019,41(3):1586-1602.
|
|
[30] XING X,HUANG Y,WANG S,et al. Comparative analysis of primary hepatocellular carcinoma with single and multiple lesions by i TRAQ-based quantitative proteomics[J]. J Proteomics,2015,128:262-271.
|
|
[31] HORIGUCHI Y,ARAKI M,MOTOJIMA K. 17beta-hydroxysteroid dehydrogenase type 13 is a liver-specific lipid droplet-associated protein[J]. Biochem Biophys Res Commun,2008,370(2):235-238.
|
|
[32] ROTROFF DM,PIJUT SS,MARVEL SW,et al. Genetic variants in HSD17B3,SMAD3,and IPO11 impact circulating lipids in response to fenofibrate in individuals with type 2 diabetes[J]. Clin Pharmacol Ther,2018,103(4):712-721.
|
|
[33] YOUNOSSI Z,HENRY L. Contribution of alcoholic and nonalcoholic fatty liver disease to the burden of liver-related morbidity and mortality[J]. Gastroenterology,2016,150(8):1778-1785.
|
DownLoad: